Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Characterisation of a Small Non-Competitive Peptide Inhibitor of IL-1RI in Preterm Labor

FY 2014-15

Summary
Inflammation is firmly linked to preterm labor (PTL) and term labor (TL) independently of the presence of infection. Pro-inflammatory cytokines including IL-1, are implicated in the induction of uterine activation proteins (UAP) within the uterus, which contribute to the premature onset of labor. Available tocolytics target uterine contractions once they are already started and are inefficient. A most promising approach to prevent PTL is to tackle inflammatory events accountable for the premature activation of the uterus, without compromising normal TL. Since Interleukin (IL)-1 has been shown to be the principal mediator of the inflammatory response in PTL, inhibiting its action would be a promising solution. However, available IL-1 targeting therapies are all competitive and thus cause a complete inhibition of IL-1 signalling including NF-?B activity, hence causing immunosuppressive effects undesirable in pregnancy for mother and fragile fetus/newborn. Several studies have reported deleterious (pro-apoptotic) effects of inhibiting NF-?B in pregnancy. Hence, avoiding its inhition is desirable. The host laboratoy developed a small (stable peptide) non-competitive IL-1 receptor antagonist, termed 101.10, demonstrating functional selectivity toward specific intracellular pathways of IL-1 receptor and efficacy in multiple inflammatory disease models. Preliminary data show that 101.10 is efficient at delaying IL-1-induced PTL without significant effects on NF-kB activity. We plan to highlight the benefits of using a non-competitive modulator of IL-1 receptor in PTL.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331286
Name
Nadeau-Vallée Mathieu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterisation of a Small Non-Competitive Peptide Inhibitor of IL-1RI in Preterm Labor
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allosterism; Functionnal Selectivity; Immunology; Inflammation; Interleukin-1; Myometrium; Pharmacology; Preterm Birth; Preterm Labor; Reproduction
Abstract
Inflammation is firmly linked to preterm labor (PTL) and term labor (TL) independently of the presence of infection. Pro-inflammatory cytokines including IL-1, are implicated in the induction of uterine activation proteins (UAP) within the uterus, which contribute to the premature onset of labor. Available tocolytics target uterine contractions once they are already started and are inefficient. A most promising approach to prevent PTL is to tackle inflammatory events accountable for the premature activation of the uterus, without compromising normal TL. Since Interleukin (IL)-1 has been shown to be the principal mediator of the inflammatory response in PTL, inhibiting its action would be a promising solution. However, available IL-1 targeting therapies are all competitive and thus cause a complete inhibition of IL-1 signalling including NF-?B activity, hence causing immunosuppressive effects undesirable in pregnancy for mother and fragile fetus/newborn. Several studies have reported deleterious (pro-apoptotic) effects of inhibiting NF-?B in pregnancy. Hence, avoiding its inhition is desirable. The host laboratoy developed a small (stable peptide) non-competitive IL-1 receptor antagonist, termed 101.10, demonstrating functional selectivity toward specific intracellular pathways of IL-1 receptor and efficacy in multiple inflammatory disease models. Preliminary data show that 101.10 is efficient at delaying IL-1-induced PTL without significant effects on NF-kB activity. We plan to highlight the benefits of using a non-competitive modulator of IL-1 receptor in PTL.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nadeau-Vallée, Mathieu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~